Dimed S.A. Distribuidora de Medicamentos

What it is

Founded in 1967, Grupo Panvel runs three interlocking businesses: the Panvel pharmacy chain, a drugs-and-beauty distributor (Dimed), and a cosmetics laboratory called Lifar. The listed entity, Dimed S.A., is the legal umbrella that consolidates all three.

The Panvel drugstore chain now has more than 500 stores across Rio Grande do Sul, Santa Catarina, Paraná and São Paulo, offering more than 15,000 medicines and personal-care items. Panvel has operated as a fully omnichannel retailer since 2015, blending physical stores with a growing digital operation.

The Dimed distribution arm runs two strategically placed centres — in Eldorado do Sul (RS) and São José dos Pinhais (PR) — and the Lifar laboratory manufactures roughly one-third of the products Panvel sells under its own label.

Who owns it

Insiders — the founding family and management — together hold about 45% of the shares, with institutional investors accounting for a further 20%, leaving a free float of roughly 34% (our calculation from structured data). The stock trades on B3’s Novo Mercado segment, Brazil’s highest tier of corporate governance.

The Mottin family is the controlling force: the current Chairman of the Board began his career at the company in 1967 — the year Grupo Panvel was founded — working up from HR assistant to CEO before taking the chair. The company’s original IPO dates to 1977; in July 2020 it completed a Re-IPO and graduated to Novo Mercado.

Who runs it

CEO Julio Ricardo Mottin Neto leads the executive team, keeping management firmly within the founding family’s orbit. CFO Antonio Carlos Tocchetto Napp handles the finances and has been the public voice on pharmacy-sector regulatory developments.

One board member who is also a shareholder of Grupo Panvel brings a 33-year executive career at Panvel to the table, having held senior roles across retail, distribution, logistics, manufacturing and governance. The board includes independent directors with backgrounds in pharmacy retail and private equity.

The money, in plain words

Sales grew from R$4.46 billion (US$866 mn) (~$866 million) in 2023 to R$5.51 billion (US$1.1 bn) (~$1.07 billion) in 2025 — a rise of 23.6% over two years (our calculation). The most recent year alone added 11.5% (our calculation), healthy in a market where rivals are fighting hard for every percentage point.

The company keeps about 2.3 cents of profit from every real of sales — a net profit margin of 2.3%, thin by global standards but typical for pharmacy retail worldwide, where volume and scale do the work. For every real shareholders own, the business earns back about 10 cents a year — a return on equity of 10.4%, moderate and improving.

The balance sheet carries a net debt load of R$1.46 billion (US$283 mn) (~$284 million, our calculation: cash of R$43.7 million (US$8 mn) minus gross debt of R$1.51 billion (US$293 mn)). That is significant relative to annual profit, so any slowdown in cash generation would tighten the room for manoeuvre.

At a price-to-earnings ratio of 12.4×, the market values the stock at a modest premium to book — not expensive for a growing retail chain, but the thin margin leaves little cushion if costs surprise.

What it is doing now

Dimed released Q4 2025 earnings on 20 March 2026, reporting 17% full-year sales growth and a record quarterly operating profit of nearly R$105 million (US$20 mn), up 28% quarter-on-quarter. Digital sales made up 54% of Q4 revenue, with online channels accounting for 28.5% of full-year sales overall.

Weight-loss drugs such as Mounjaro now represent 11% of Dimed’s sales, with supply restrictions from manufacturers gradually easing as Brazil gains higher priority from suppliers like Lilly. CEO Mottin Neto has set out a target to double revenue to R$12 billion (US$2.3 bn) by 2030, expanding to 1,000 stores while lifting operating margins to 7%.

Panvel’s own-label products already drive nearly 20% of hygiene and beauty sales, helping protect margins against generic-drug price pressure. The company opened 51 new stores over the past year.

What to watch

• Debt service vs. growth spending. Opening 500 more stores while carrying R$1.46 billion (US$283 mn) in net debt will test cash generation; watch quarterly free cash flow closely.
• Weight-loss drug dynamics. GLP-1 drugs carry lower margins than core pharmacy lines, and the counterfeit market is estimated to be three times larger than formal channels — a risk to both revenue and brand trust if counterfeit-GLP-1 events make headlines.
• Generics expansion. CFO Napp has flagged that generic equivalents entering the GLP-1 category around June 2026 could expand the addressable market threefold, which would be strongly positive for volume if managed well.
• Regional concentration. Panvel holds roughly 14% market share in southern Brazil — strong there, but the 2030 doubling target requires meaningful penetration outside its home territory.
• Dividend resumption. The current yield is 0%; bylaws guarantee a minimum 25% payout of adjusted net income once declared. Rising profitability could restart distributions and attract income investors.

This is news, not investment advice.